What happened
Par Health announced a voluntary nationwide recall to the hospital level of two lots of Dexmedetomidine HCl in 0.9% Sodium Chloride Injection, 400 mcg/100 mL, after particulate matter was identified as cellulose or stopper material. The affected lots are 87558, expiring February 2027, and 88802, expiring April 2027. They were distributed to wholesalers between May 13 and June 29, 2025. Wholesalers and hospital pharmacies were instructed to stop use and distribution and return existing inventory. The announcement states that particulate administration could cause life-threatening vascular consequences. No related adverse events had been reported.
Why it matters
From a GMP and pharmaceutical manufacturing perspective, particulate matter in an intravenous product may warrant attention to contamination controls and possible sources associated with cellulose or stopper material. The recall also highlights the importance of lot-level distribution traceability and inventory control when affected injectable products must be identified, removed from use, returned, and communicated through downstream accounts. The source does not identify the underlying manufacturing cause.
Key topics: particulate matter in dexmedetomidine injection, cellulose or stopper material, hospital-level recall of lots 87558 and 88802